LGND

Ligand Pharmaceuticals Incorporated Press Releases

$63.58
*  
8.51
15.45%
Get LGND Alerts
*Delayed - data as of Mar. 2, 2015  -  Find a broker to begin trading LGND now
Exchange: NASDAQ
Industry: Health Care
Community Rating:
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks
Viewing
Filtered By
Ordered By
Spectrum Pharmaceuticals Highlights Clinical Data for Captisol-Enabled™ (Propylene Glycol-Free) Melphalan at the 2015 BMT Tandem Meeting
2/12/2015 7:00:00 AM - Business Wire


Ligand Reports Fourth Quarter and Full Year 2014 Financial Results
2/9/2015 8:30:00 AM - Business Wire


Ritter Pharmaceuticals Names Matthew W. Foehr to Its Board of Directors
2/9/2015 7:00:00 AM - Business Wire


Ligand Partner GlaxoSmithKline Announces EU Regulatory Submission Seeking Additional Indication for Revolade®
2/6/2015 9:15:00 AM - Business Wire


Ligand Signs License Agreement with Sermonix for Lasofoxifene
2/3/2015 8:30:00 AM - Business Wire


Ligand Promotes Matthew W. Foehr to President
2/2/2015 4:30:00 PM - Business Wire


Ligand to Present at BIO CEO and RBC Capital Markets Global Healthcare Conferences in February
1/28/2015 8:30:00 AM - Business Wire
▲8.57 % Price Change since this news event. The Volume Ratio is 0.77.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Ligand to Report Fourth Quarter Results on February 9th
1/27/2015 9:00:00 AM - Business Wire
▲12.41 % Price Change since this news event. The Volume Ratio is 1.68.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Ligand Partner Retrophin Receives Orphan Drug Designation for Sparsentan
1/9/2015 10:15:00 AM - Business Wire
▲18.18 % Price Change since this news event. The Volume Ratio is 1.66.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Ligand Partner Melinta Therapeutics Reports Positive Phase 3 Results for Captisol-enabled™ Delafloxacin IV
1/8/2015 8:30:00 AM - Business Wire
▲18.31 % Price Change since this news event. The Volume Ratio is 1.52.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Ligand Partner Spectrum Pharmaceuticals Announces Submission of New Drug Application for Captisol-Enabled™ Melphalan
12/26/2014 7:30:00 AM - Business Wire
▲22.77 % Price Change since this news event. The Volume Ratio is 0.58.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Spectrum Pharmaceuticals Files a New Drug Application with the FDA for Captisol-Enabled™ (Propylene Glycol-Free) Melphalan
12/26/2014 7:00:00 AM - Business Wire


Ligand Partner GlaxoSmithKline Announces US Regulatory Submission Seeking Additional Indication for Promacta®
12/22/2014 9:20:00 AM - Business Wire
▲20.42 % Price Change since this news event. The Volume Ratio is 0.58.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Ligand Partner Pfizer Receives European Marketing Authorization for DUAVIVE® (Conjugated Estrogens/Bazedoxifene) for Treatment of Estrogen Deficiency Symptoms in Postmenopausal Women with a Uterus
12/19/2014 11:30:00 AM - Business Wire
▲20.58 % Price Change since this news event. The Volume Ratio is 2.78.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day